Article
Oncology
Michelle Ertel, S. Allison Staley, Tam Nguyen, Austin Johnson, Austin Hopkins, Nerlyne Desravines, Johnathon Recknagel, Xinyi Zhang, Xianming Tan, Leslie H. Clark
Summary: The study found that the incidence of medical inoperability in clinical stage I endometrial cancer was 4.6%, with factors such as high body mass index, diabetes, coronary artery disease, and hypertension increasing the risk of inoperability. Despite maximal surgical effort and minimally invasive surgery achieving hysterectomy in over 95% of patients, there was a complication rate of 11.6%.
ANNALS OF SURGICAL ONCOLOGY
(2021)
Review
Gastroenterology & Hepatology
Katherine A. McGlynn, Jessica L. Petrick, Hashem B. El-Serag
Summary: Liver cancer, particularly hepatocellular carcinoma (HCC), is a major global health concern. While HBV and HCV remain important risk factors for HCC, efforts in vaccination and treatment are showing promise. However, the increasing prevalence of metabolic risk factors like obesity and diabetes, as well as other factors like excessive alcohol consumption, present ongoing challenges in the prevention of liver cancer.
Article
Gastroenterology & Hepatology
Summary: Hepatocellular carcinoma (HCC) is the fifth most common cancer worldwide and the fourth most common cancer among men in South Korea. The revised Korean guidelines integrate the most up-to-date research findings and expert opinions, providing useful advice and guidance for the clinical management of HCC.
CLINICAL AND MOLECULAR HEPATOLOGY
(2022)
Review
Oncology
Isabella Angeli-Pahim, Anastasia Chambers, Sergio Duarte, Ali Zarrinpar, Hiromitsu Hayashi, Yutaka Midorikawa
Summary: Hepatocellular carcinoma (HCC) is a leading cause of cancer-related deaths worldwide. Surgical management, including hepatic resection, liver transplantation, and ablation, offers the greatest potential for a curative approach. This review discusses recent advancements in HCC surgery, including criteria expansion, minimally invasive surgery, improved visualization techniques, and novel approaches for optimizing future liver remnant and managing hemorrhage. The review also explores the debate surrounding liver transplantation criteria and presents alternative proposals. Additionally, emerging ablation techniques are compared to the standard radiofrequency ablation. Overall, this comprehensive review provides valuable insights into the current trends and future prospects in HCC surgical management.
Review
Gastroenterology & Hepatology
Riccardo Inchingolo, Fabrizio Acquafredda, Michele Tedeschi, Letizia Laera, Gianmarco Surico, Alessia Surgo, Alba Fiorentino, Stavros Spiliopoulos, Nicola de'Angelis, Riccardo Memeo
Summary: The COVID-19 pandemic has impacted hospital organization, leading to modifications in the management of oncological patients, including different allocation of nurses and doctors, and requiring new strategies to ensure correct assistance for patients. Additionally, hepatocellular carcinoma, considered one of the most aggressive types of liver cancer, has also required different management during this period in order to optimize care for patients at risk.
WORLD JOURNAL OF GASTROENTEROLOGY
(2021)
Article
Radiology, Nuclear Medicine & Medical Imaging
Joong-Won Park
Summary: This article introduces the incidence of hepatocellular carcinoma (HCC) worldwide and in South Korea, where the prevalence of chronic hepatitis B infection is high. The authors also discuss the latest clinical management guidelines and emphasize their role in guiding diagnosis and treatment.
KOREAN JOURNAL OF RADIOLOGY
(2022)
Review
Gastroenterology & Hepatology
Luckshi Rajendran, Tommy Ivanics, Marco P. A. W. Claasen, Hala Muaddi, Gonzalo Sapisochin
Summary: The annual incidence of hepatocellular carcinoma (HCC) is increasing, and liver transplantation is the preferred treatment. However, there is currently no consensus on post-transplantation cancer surveillance and recurrence management for HCC. Early tumor detection, re-evaluation of immunosuppression regimens, and staging are important for guiding decision-making and maximizing treatment effect. Treatment recommendations specific to recurrence type are provided.
CLINICAL AND MOLECULAR HEPATOLOGY
(2022)
Review
Medicine, General & Internal
Tharusan Thevathasan, Teresa Colbatzky, Moritz Schmelzle, Johann Pratschke, Felix Krenzien
Summary: This study protocol aims to identify risk factors and their risk estimates for the transformation from hepatocellular adenomas (HCAs) to hepatocellular carcinoma (HCC) through a systematic review and meta-analysis. Data from studies published between 1970 and 2021 will be analyzed, with primary outcome being the odds ratio (OR) of developing HCC in patients with prediagnosed HCA based on exposure to risk factors. Results will be disseminated in a peer-reviewed journal upon completion.
Review
Gastroenterology & Hepatology
Bo Hyun Kim, Su Jong Yu, Wonseok Kang, Sung Bum Cho, Soo Young Park, Seung Up Kim, Do Young Kim
Summary: Lenvatinib is an oral multikinase inhibitor approved for first-line treatment of advanced hepatocellular carcinoma. Common adverse events include hypertension, diarrhea, hand-foot skin reaction, and proteinuria. Effective management of these events involves prophylactic measures, regular monitoring, and dose adjustment based on the severity of the event.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
(2022)
Review
Oncology
Flavio Milana, Michela Anna Polidoro, Simone Famularo, Ana Lleo, Renzo Boldorini, Matteo Donadon, Guido Torzilli
Summary: Hepatocellular carcinoma (HCC) is the most common primary liver cancer, and both liver resection and liver transplantation are considered potentially curative options. The management of HCC recurrence is still not well defined, but surgery remains a curative option for selected patients. This study aimed to summarize the patterns and histopathological characteristics of HCC recurrence, their prognostic value, and the main surgical strategies for dealing with HCC relapse.
Article
Gastroenterology & Hepatology
Maria Reig, Giuseppe Cabibbo
Summary: The potential impact of DAAs in BCLC-B/C stage patients with HCC is understudied, as HCC patients have been excluded from DAA trials. The decision on using DAAs should be made based on individual patient profiles.
JOURNAL OF HEPATOLOGY
(2021)
Review
Gastroenterology & Hepatology
Aurelie Beaufrere, Julien Calderaro, Valerie Paradis
Summary: Combined hepatocellular-cholangiocarcinoma (cHCC-CCA) is a tumor with both hepatocytic and biliary differentiation, whose diagnosis is primarily based on morphology and immunostaining, with a prognosis worse than hepatocellular carcinoma and treatment limited to surgery.
JOURNAL OF HEPATOLOGY
(2021)
Article
Radiology, Nuclear Medicine & Medical Imaging
Fei Wu, Xiaoyan Ni, Haitao Sun, Changwu Zhou, Peng Huang, Yuyao Xiao, Li Yang, Chun Yang, Mengsu Zeng
Summary: This study aimed to determine clinicoradiological prognostic factors for patients with MHCC beyond the Milan criteria and develop a stratification system. MRI features and preoperative laboratory data of 176 patients were collected and analyzed, and two nomograms were constructed to predict RFS and OS. Based on the nomograms, patients were stratified into low-/medium-/high-risk groups, and significant differences in RFS and OS were observed among these groups.
JOURNAL OF MAGNETIC RESONANCE IMAGING
(2023)
Article
Gastroenterology & Hepatology
Ihab Kassab, Amit G. Singal, Aamir Ali, Manasa Narasimman, Ashwini Arvind, Muneeb Ahmed, Sagar Joshi, Komal Manzoor, Nicole Rich, Vincent L. Chen, Zhe Zhao, Ammar Sarwar, Neehar D. Parikh
Summary: This study suggests that stage migration could serve as a potential surrogate of overall survival in patients undergoing transarterial chemoembolization (TACE) for hepatocellular carcinoma (HCC).
HEPATOLOGY COMMUNICATIONS
(2023)
Review
Oncology
Lea Muzellec, Heloise Bourien, Julien Edeline
Summary: Hepatocellular carcinoma (HCC) is a serious disease with limited curative treatment options. Quality of life plays a crucial role in the prognosis of the disease, and its impact has been demonstrated. Specific tools have been developed to assess quality of life, and systemic treatments and cancer progression can decrease it. Authorities now require not only efficacy but also improvement in quality of life for approval of new treatments. This review provides data on quality of life in HCC, including specific tools, impact of treatments, and prognosis. Management of adverse events is essential to enhance treatment compliance and quality of life. Although quality of life assessment is common in clinical trials, its application in clinical routine still needs further development.
Article
Gastroenterology & Hepatology
Mohammad A. Karim, Amit G. Singal, Hye Chung Kum, Yi-Te Lee, Sulki Park, Nicole E. Rich, Mazen Noureddin, Ju Dong Yang
Summary: NAFLD is the leading cause of HCC among Medicare beneficiaries, accounting for 35.6% of cases. Compared to HCC related to hepatitis C, NAFLD-associated HCC had lower surveillance receipt, later stage detection, and slightly poorer survival. Multifaceted interventions are needed to improve surveillance uptake and prognosis for NAFLD-related HCC.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY
(2023)
Article
Gastroenterology & Hepatology
Fasiha Kanwal, Saira Khaderi, Amit G. Singal, Jorge A. Marrero, Nicole Loo, Sumeet K. Asrani, Christopher Amos, Aaron P. Thrift, Xiangjun Gu, Michelle Luster, Abeer Al-Sarraj, Jing Ning, Hashem B. El-Serag
Summary: This study investigated the risk of developing HCC in patients with cirrhosis and found that the incidence rate of HCC was lower than previously reported. The risk of HCC varied depending on the etiology, with higher risk in patients with cured HCV and lower risk in those with NAFLD. Current smoking and overweight/obesity were also associated with increased HCC risk.
Article
Gastroenterology & Hepatology
Nikita Sandeep Wagle, Sulki Park, David Washburn, Robert L. Ohsfeldt, Nicole E. Rich, Amit G. Singal, Hye-Chung Kum
Summary: This study found that treatment delays are prevalent in patients with hepatocellular carcinoma (HCC) and are associated with worse survival. Treatment delays varied across different treatment modalities and were more likely to occur in Black patients and those living in high poverty neighborhoods. The results highlight the importance of interventions to improve time-to-treatment.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY
(2023)
Article
Oncology
Sandi L. Pruitt, Anna Tavakkoli, Hong Zhu, Daniel F. Heitjan, David E. Gerber, Amit G. Singal, Ethan A. Halm, Muhammad Shaalan Beg, Bhumika Maddineni, Ankit J. Kansagra, Caitlin C. Murphy
Summary: Pancreas cancer patients who have previously had another cancer have similar survival rates to those without previous cancer, suggesting that cancer survivors should be considered for inclusion in pancreas cancer clinical trials.
Article
Oncology
Andrew M. Brown, Ihab Kassab, Marco Massani, Whitney Townsend, Amit G. Singal, Cigdem Soydal, Laura Moreno-Luna, Lewis R. Roberts, Vincent L. Chen, Neehar D. Parikh
Summary: This study conducted an overall and individual patient data (IPD) meta-analysis of transarterial radioembolization (TARE) and transarterial chemoembolization (TACE) for the treatment of hepatocellular carcinoma (HCC). The results showed that TARE had a significantly longer time to progression (TTP) compared to TACE, but there was no significant difference in overall survival (OS) between the two modalities. The limitations of the current data include inconsistent length of follow-up and response criteria. Therefore, prospective studies comparing these treatments are needed.
Editorial Material
Gastroenterology & Hepatology
Amit G. Singal, Neehar D. Parikh, Yujin Hoshida
DIGESTIVE DISEASES AND SCIENCES
(2023)
Article
Gastroenterology & Hepatology
Mohammad A. Karim, Mahin Ramezani, Todd Leroux, Hye-Chung Kum, Amit G. Singal
Summary: This study aimed to assess the financial burden of hepatocellular carcinoma (HCC) in the United States. Through analyzing a cohort of 4525 adult patients diagnosed with HCC between 2011 and 2015, it was found that HCC patients had significantly higher healthcare costs and patient liabilities in the first year after diagnosis. Additionally, early-stage HCC patients had lower incremental costs compared to those with larger tumor burden.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY
(2023)
Article
Public, Environmental & Occupational Health
Caitlin C. Murphy, Piera M. Cirillo, Nickilou Y. Krigbaum, Amit G. Singal, Dean P. Jones, Timothy Zaki, Barbara A. Cohn
Summary: This study examined the association between in-utero exposure to antibiotics and the risk of colorectal cancer (CRC) in adult offspring. The findings suggest that in-utero exposure to long-acting sulfonamides is associated with an increased risk of CRC in adulthood.
INTERNATIONAL JOURNAL OF EPIDEMIOLOGY
(2023)
Article
Multidisciplinary Sciences
Aaron P. Thrift, Fasiha Kanwal, Yanhong Liu, Saira Khaderi, Amit G. Singal, Jorge A. Marrero, Nicole Loo, Sumeet K. Asrani, Michelle Luster, Abeer Al-Sarraj, Jing Ning, Spiridon Tsavachidis, Xiangjun Gu, Christopher I. Amos, Hashem B. El-Serag
Summary: This study found that polygenic risk scores can be used to predict the risk of hepatocellular cancer in contemporary U.S. cirrhosis patients and can improve the predictive ability of traditional risk factor models.
Article
Chemistry, Multidisciplinary
Yifei Tan, Jianhui Zhu, Cristian D. Gutierrez Reyes, Yu Lin, Zhijing Tan, Zuowei Wu, Jie Zhang, Alva Cano, Sara Verschleisser, Yehia Mechref, Amit G. Singal, Neehar D. Parikh, David M. Lubman
Summary: Aberrant changes in site-specific core fucosylation (CF) of serum proteins can serve as potential diagnostic markers of tumors. A study employed an optimized data-dependent acquisition (DDA) workflow to identify CF of serum proteins in patients with nonalcoholic steatohepatitis-related cirrhosis and hepatocellular carcinoma. The study found significant changes in CF peptides between cirrhosis and HCC, with one peptide showing the best diagnostic performance in discriminating HCC from cirrhosis.
Article
Gastroenterology & Hepatology
Amit G. Singal, T. Tara Ghaziani, Neil Mehta, Kali Zhou, Lauren T. Grinspan, Jihane N. Benhammou, Andrew M. Moon, Ju Dong Yang, Reena Salgia, Anjana Pillai, Elizabeth Zheng, Nicole E. Rich, Purva Gopal, Prasun Jalal, Elizabeth Verna, Sruthi Yekkaluri, Samuel Phen, Jonathan Melendez-Torres, Omar Alshuwaykh, Hailey Choi, Kevin Junus, John Grady, Michael Song, Emily A. Leven, Jung Yum, Vrushab Gowda, Manaf Alsudaney, Perla Hernandez, Nirmal Desai, Neehar D. Parikh
Summary: There is a wide variation in recall patterns for patients with subcentimeter liver lesions on ultrasound. The low risk of primary liver cancer (PLC) in these patients supports short-interval ultrasound follow-up in 3-6 months, but high-risk subgroups may require diagnostic CT/MRI.
HEPATOLOGY COMMUNICATIONS
(2023)
Article
Oncology
Caitlin C. Murphy, Piera M. Cirillo, Nickilou Y. Krigbaum, Amit G. Singal, Barbara A. Cohn
Summary: This study found that offspring exposed to Bendectin in utero had a higher risk of colorectal cancer (CRC) compared to unexposed offspring. The increased risk may be due to the presence of dicyclomine in Bendectin. Further experimental studies are needed to confirm these findings and identify the mechanisms of risk.
JNCI CANCER SPECTRUM
(2023)
Article
Multidisciplinary Sciences
Noa Kopplin, Angie Garcia, Annika Reczek, Kate Wilkinson, Sruthi Yekkaluri, Caitlin C. Murphy, Jasmin Tiro, Alagar R. Muthukumar, Andrew Masica, Amit G. Singal
Summary: This study investigated the natural history and sequelae symptoms of mild COVID-19 infection. More than one in five patients reported persistent symptoms during follow-up. Levels of anti-nucleocapsid and anti-spike antibodies decreased within six months following infection and vaccination.
Article
Gastroenterology & Hepatology
Andrew M. Moon, Sarah Cook, Rachel M. Swier, Hanna K. Sanoff, Michael D. Kappelman, Lynne I. Wagner, A. Sidney Barritt, Amit G. Singal, Neil D. Shah, David M. Mauro, Ted K. Yanagihara, David A. Gerber, Michael W. Fried, Cristal Brown, Myra Waheed, Randall Teal, Donna M. Evon
Summary: This study found that posttreatment symptoms after locoregional therapies in HCC patients are common and often severe. These findings can help prioritize patient-reported outcomes (PRO) domains and suggest that patients are interested in electronic PRO symptom monitoring. Further investigation of electronic PRO monitoring in HCC patients is warranted.
HEPATOLOGY COMMUNICATIONS
(2023)
Article
Oncology
Mohammad A. Karim, Amit G. Singal, Hye Chung Kum, Yi-Te Lee, Sulki Park, Nicole E. Rich, Mazen Noureddin, Ju Dong Yang
Summary: Prediagnostic CT or MRI is associated with improved survival in patients with HCC, with CT/MRI showing a greater benefit compared to ultrasound in early detection.
CANCER RESEARCH COMMUNICATIONS
(2023)